Abbott Expects To Resume Shipments Of Recalled MitraClip In Several Months
This article was originally published in The Gray Sheet
Executive Summary
Abbott expects it will take several months to resume shipments of its MitraClip transcatheter mitral valve repair system following a voluntary global recall, but the firm says the recall is not likely to impact anticipated U.S. approval of the device later this year.
You may also be interested in...
Four Firms Vie For Medicare 2014 New-Tech Add-On Payments
CMS held its annual new-technology Town Hall February 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.
FDA Advisory Panel Will Evaluate Abbott’s MitraClip Next Month
Abbott to present data showing MitraClip is safer option for inoperable patients.
Four Firms Vie For Medicare 2014 New-Tech Add-On Payments
CMS held its annual new-technology Town Hall Feb. 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.